Tesamorelin

[POPO]

Key Clinically Approved Effects (FDA Indication: Visceral Fat Accumulation in HIV Patients)

Reducing Visceral Abdominal Fat
Specifically targets visceral fat (deep abdominal fat), not subcutaneous fat. In a 26-week clinical trial, visceral fat area significantly decreased, with the most noticeable reduction in abdominal visceral fat; its effect on subcutaneous fat reduction is limited, and rapid weight loss is not guaranteed.

Improving Body Composition
Slightly increases lean muscle mass and reduces body fat; muscle gain is moderate, not a potent muscle-building peptide, and will not cause the rapid muscle growth seen with anabolic steroids.

Improved Sleep and Energy
Administered at night, matching the body's GH secretion rhythm at night, many users reported deeper sleep and improved daytime energy; effects vary from person to person.

Slightly Improved Lipid Metabolism
Some subjects experienced a decrease in triglycerides.

Effects Expected in the Public, but with Limited Clinical Evidence

Anti-aging and Anti-aging: Not approved, insufficient evidence; only observed increase in IGF-1, which does not represent a real anti-aging benefit.

Fat loss and body shaping: Highly effective only for visceral fat; generally less effective for average obesity, and may not be noticeable if you only want to lose belly fat.

Joint repair: Only indirectly and weakly assists, far less effective than BPC-157/TB500.